DR. SAHEBAAN SABHARWAL

Abstract

Aim: Evaluating clinical outcomes and safety of stand-alone iStent inject implant in open angle glaucoma. iStent inject has been launched in India only 8 months ago.

Method: A prospective longitudinal case series included consecutive iStent inject cases from a single surgeon at a tertiary care hospital. Intraocular pressure(IOP), medications and safety profile was assessed.

Results: Preoperative mean IOP was 21.33mmHg on 4 mean medications. Mean IOP reduction was 21.84% and reduction in medications was by 25% in 2 and 50% in 1 case at 1 month follow up. 3 month results will be shortly procured. There were no major side effects except initial IOP spikes.

Conclusion: This is the first pilot study from India on stand-alone iStent inject results.

iStent inject produced significant IOP reduction and number of medications when performed as a stand alone procedure in phakic or pseudophakic patients with excellent safety profile. It has the potential to revolutionize glaucoma management.